pre-miRNA Information
pre-miRNA hsa-mir-4656   
Genomic Coordinates chr7: 4788565 - 4788639
Description Homo sapiens miR-4656 stem-loop
Comment None
RNA Secondary Structure

Mature miRNA Information
Mature miRNA hsa-miR-4656
Sequence 10| UGGGCUGAGGGCAGGAGGCCUGU |32
Evidence Experimental
Experiments Illumina
SNPs in miRNA
Mutant ID Mutant Position Mutant Source
rs1257485407 2 dbSNP
rs71535143 5 dbSNP
rs933178228 7 dbSNP
rs895666746 9 dbSNP
rs1053330554 11 dbSNP
rs1327822621 13 dbSNP
rs934599733 16 dbSNP
rs1260841927 19 dbSNP
rs1371177672 22 dbSNP
Putative Targets

miRNA Expression profile
Human miRNA Tissue Atlas
Circulating MicroRNA Expression Profiling
Gene Information
Gene Symbol SLC10A3   
Synonyms DXS253E, P3
Description solute carrier family 10 member 3
Transcript NM_001142391   
Other Transcripts NM_001142392 , NM_019848   
Expression
Putative miRNA Targets on SLC10A3
3'UTR of SLC10A3
(miRNA target sites are highlighted)
>SLC10A3|NM_001142391|3'UTR
   1 GGCCTCTGGGTCAAGCTTTCATCAGCCCCAGCCCCCACACTCCACCAAAGTTCTCATGCACTATGCACTCAGAAAAATCC
  81 AGGCTTATTTTTTTTACTGATTTTTTATTCTCCAGCTTTCAGTGCCAAAGAGGCCATGCTGAGTTAGGTAGGTGGGCGCT
 161 GCCCAGAAAATATATTTCAATAAAAGAGAGAAGCAAGCTTGAAAAAAAAAAAAAAAAAA
Target sites Provided by authors   Predicted by miRanda    DRVs    SNPs    DRVs & SNPs
miRNA-target interactions
(Predicted by miRanda)
ID Duplex structure Position Score MFE
1
miRNA  3' uguCCGGAG---------GACGGGAGUCGGGu 5'
             ||||||         || :| ||||||| 
Target 5' ---GGCCTCTGGGTCAAGCTTTCATCAGCCCc 3'
1 - 29 156.00 -23.70
2
miRNA  3' uguccGGAGGACGGGAGUCGGGu 5'
               :|||| ||::||||: | 
Target 5' tttatTCTCCAGCTTTCAGTGCc 3'
104 - 126 122.00 -21.20
3
miRNA  3' uguccggaggacgggaGUCGGGu 5'
                          | |||| 
Target 5' gttaggtaggtgggcgCTGCCCa 3'
143 - 165 88.00 -16.60
SNPs in gene 3'UTRs
Mutant ID Mutant Position Mutant Source
rs1235261375 7 dbSNP
rs1293943985 8 dbSNP
rs1328779348 16 dbSNP
rs782656612 26 dbSNP
rs1262274110 32 dbSNP
rs782503551 36 dbSNP
rs781846179 45 dbSNP
rs782715086 51 dbSNP
rs11550365 53 dbSNP
rs1476126565 69 dbSNP
rs1188079627 70 dbSNP
rs369220311 75 dbSNP
rs782699594 87 dbSNP
rs1416949247 98 dbSNP
rs1160925403 101 dbSNP
rs782120525 102 dbSNP
rs1454681098 106 dbSNP
rs1312621177 119 dbSNP
rs1048969 130 dbSNP
rs1374205346 130 dbSNP
rs1417111936 136 dbSNP
rs1313576141 158 dbSNP
rs1372614335 170 dbSNP
rs1222136186 172 dbSNP
rs1309496067 173 dbSNP
rs1317720910 174 dbSNP
rs1232306524 186 dbSNP
rs1277870497 192 dbSNP
Experimental Support 1 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions BC-1
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... PAR-CLIP data was present in GSM796037. RNA binding protein: AGO2. Condition:4-Thiouridine PAR-CLIP data was present in GSM796038. RNA binding protein: AGO2. Condition:4-Thiouridine ...

- Gottwein E; Corcoran DL; Mukherjee N; et al., 2011, Cell host & microbe.

miRNA-target interactions (Provided by authors)
ID Duplex structure Position
1
miRNA  3' uguccggagGACGGGAGUCgggu 5'
                   || :| ||||    
Target 5' ----ucaagCUUUCAUCAG---- 3'
1 - 15
Article - Gottwein E; Corcoran DL; Mukherjee N; et al.
- Cell host & microbe, 2011
Primary effusion lymphoma (PEL) is caused by Kaposi's sarcoma-associated herpesvirus (KSHV) and frequently also harbors Epstein-Barr virus (EBV). The expression of KSHV- and EBV-encoded microRNAs (miRNAs) in PELs suggests a role for these miRNAs in latency and lymphomagenesis. Using PAR-CLIP, a technology which allows the direct and transcriptome-wide identification of miRNA targets, we delineate the target sites for all viral and cellular miRNAs expressed in PEL cell lines. The resulting data set revealed that KSHV miRNAs directly target more than 2000 cellular mRNAs, including many involved in pathways relevant to KSHV pathogenesis. Moreover, 58% of these mRNAs are also targeted by EBV miRNAs, via distinct binding sites. In addition to a known viral analog of cellular miR-155, we show that KSHV encodes a viral miRNA that mimics cellular miR-142-3p function. In summary, this study identifies an extensive list of KSHV miRNA targets, which are likely to influence viral replication and pathogenesis.
LinkOut: [PMID: 22100165]
Experimental Support 2 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions Prostate Tissue
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... PAR-CLIP data was present in SRX1760620. RNA binding protein: AGO2. Condition:AGO-CLIP-LAPC4_A ...

- Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al., 2016, Neoplasia (New York, N.Y.).

Article - Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al.
- Neoplasia (New York, N.Y.), 2016
MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa drivers. Globally, tissue-specific and stage-specific changes in miRNA targeting are driven by homeostatic response to active oncogenic pathways. Our findings indicate that, even in advanced PCa, the miRNA pool adapts to regulate continuing alterations in the cancer genome to balance oncogenic molecular changes. These findings are important because they are the first to globally characterize miRNA changes in PCa and demonstrate how the miRNA target spectrum responds to staged tumorigenesis.
LinkOut: [PMID: 27292025]
CLIP-seq Support 1 for dataset GSM796037
Method / RBP PAR-CLIP / AGO2
Cell line / Condition BC-1 / 4-Thiouridine
Location of target site ENST00000369649.4 | 3UTR | UCAAGCUUUCAUCAGC
Tools used in this analysis TargetScan, miRTarCLIP, and Piranha
Article / Accession Series PMID: 22100165 / GSE32109
CLIP-seq Viewer Link
CLIP-seq Support 2 for dataset GSM796038
Method / RBP PAR-CLIP / AGO2
Cell line / Condition BC-1 / 4-Thiouridine
Location of target site ENST00000369649.4 | 3UTR | UCAAGCUUUCAUCAG
Tools used in this analysis TargetScan, miRTarCLIP, and Piranha
Article / Accession Series PMID: 22100165 / GSE32109
CLIP-seq Viewer Link
MiRNA-Target Expression Profile
Dataset Pearson Correlation P-value for Pearson Correlation Spearman Correlation P-value for Spearman Correlation Samples Chart
MiRNA-Target Expression Profile (TCGA)
Tumor Pearson Correlation P-value for Pearson Correlation Spearman Correlation P-value for Spearman Correlation Samples Chart
48 hsa-miR-4656 Target Genes:
Functional analysis:
ID Target Description Validation methods
Strong evidence Less strong evidence
MIRT135536 RAB5B RAB5B, member RAS oncogene family 2 2
MIRT168127 SOX4 SRY-box 4 2 2
MIRT301229 SH3BP4 SH3 domain binding protein 4 2 2
MIRT444362 TIMM8B translocase of inner mitochondrial membrane 8 homolog B 2 2
MIRT445909 SLC10A3 solute carrier family 10 member 3 2 2
MIRT447283 LAPTM5 lysosomal protein transmembrane 5 2 2
MIRT453797 KBTBD12 kelch repeat and BTB domain containing 12 2 2
MIRT456777 MTHFSD methenyltetrahydrofolate synthetase domain containing 2 2
MIRT459647 PCSK9 proprotein convertase subtilisin/kexin type 9 2 2
MIRT462333 BCL7B BCL tumor suppressor 7B 2 2
MIRT463535 ZBTB7A zinc finger and BTB domain containing 7A 2 2
MIRT465799 TMEM91 transmembrane protein 91 2 2
MIRT470647 POM121C POM121 transmembrane nucleoporin C 2 2
MIRT470837 PLXND1 plexin D1 2 2
MIRT471129 PHF19 PHD finger protein 19 2 2
MIRT483310 SLC35C2 solute carrier family 35 member C2 2 2
MIRT487264 CCNF cyclin F 2 2
MIRT491731 SEMA3F semaphorin 3F 2 2
MIRT497195 DRP2 dystrophin related protein 2 2 2
MIRT508384 SPTBN2 spectrin beta, non-erythrocytic 2 2 4
MIRT530496 FADS6 fatty acid desaturase 6 2 2
MIRT546995 PPP2CA protein phosphatase 2 catalytic subunit alpha 2 2
MIRT549790 KIAA0391 KIAA0391 2 2
MIRT560368 TAF8 TATA-box binding protein associated factor 8 2 2
MIRT566000 RNF4 ring finger protein 4 2 2
MIRT574035 PEX26 peroxisomal biogenesis factor 26 2 2
MIRT574231 DMRT2 doublesex and mab-3 related transcription factor 2 2 2
MIRT576139 Hmox1 heme oxygenase 1 2 2
MIRT576640 Mill2 MHC I like leukocyte 2 1 1
MIRT609875 RAD54L2 RAD54 like 2 2 4
MIRT622651 POU2F3 POU class 2 homeobox 3 2 4
MIRT628848 FAM151B family with sequence similarity 151 member B 2 2
MIRT634252 TIAL1 TIA1 cytotoxic granule associated RNA binding protein like 1 2 2
MIRT634672 GDE1 glycerophosphodiester phosphodiesterase 1 2 2
MIRT649087 FBXO25 F-box protein 25 2 2
MIRT665019 ELK1 ELK1, ETS transcription factor 2 2
MIRT666939 PMEPA1 prostate transmembrane protein, androgen induced 1 2 2
MIRT668960 CNBP CCHC-type zinc finger nucleic acid binding protein 2 2
MIRT675802 MED28 mediator complex subunit 28 2 2
MIRT684022 FOLR1 folate receptor 1 2 2
MIRT696480 COX6B1 cytochrome c oxidase subunit 6B1 2 2
MIRT705894 ADCY9 adenylate cyclase 9 2 2
MIRT709434 ZSCAN25 zinc finger and SCAN domain containing 25 2 2
MIRT713572 SLC2A8 solute carrier family 2 member 8 2 2
MIRT716697 HLA-B major histocompatibility complex, class I, B 2 2
MIRT719735 SLC39A11 solute carrier family 39 member 11 2 2
MIRT724907 DAO D-amino acid oxidase 2 2
MIRT725321 NFASC neurofascin 2 2
miRNA-Drug Associations
miRNA Small Melocule FDA CID Detection Method Condition PMID Year Expression Pattern of miRNA
miR-4 Dexamethasone approved 5743 Microarray primary rat thymocytes 20847043 2010 up-regulated
miRNA-Drug Resistance Associations
miRNA Drug Name CID NSC FDA Effect/Pattern Detection Method Level Phenotype Condition
hsa-miR-4656 Platinum 23939 sensitive High Ovarian Cancer tissue
hsa-miR-4656 Cisplatin 5460033 NSC119875 approved resistant High Hypopharyngeal Cancer cell line (FaDu)
hsa-mir-4656 Cisplatin 5460033 NSC119875 approved resistant cell line (BxPC3)
hsa-miR-4656 Doxorubicin 31703 NSC123127 approved sensitive cell line (BAS)
hsa-miR-4656 Osimertinib 71496458 NSC779217 approved resistant cell line (H1975)
hsa-miR-4656 Paclitaxel 36314 NSC125973 approved resistant cell line (A2780)
hsa-miR-4656 Cisplatin 5460033 NSC119875 approved resistant cell line (A2780)
hsa-miR-4656 Cisplatin 5460033 NSC119875 approved sensitive cell line (A2780)
hsa-miR-4656 Gemcitabine 60750 NSC613327 approved resistant cell line (MDA-231)
hsa-miR-4656 Vemurafenib 42611257 NSC761431 approved sensitive cell line (LM16)

Error report submission